Session 4 – Cross Border Investments
Date: 25 July (Thursday) 14:00 – 17:40 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Dr. Kuo-Liang Yu
Dr. Guo-Liang Yu is the global CEO of Apollomics Pharmaceuticals Inc (Formerly CBT Pharmaceuticals), an innovative therapeutics company devoted to curing cancer by combining immunology and other cancer fighting methods. Before Apollomics, Dr. Yu was the Executive Chairman of Crown Biosicence Inc., a publically-listed personalized oncology platform company with ~600 employees globally. Crown Bioscience was acquired by JSR for $400 million in January of 2018. Dr. Yu also co-founded Epitomics Inc., an antibody biotechnology company, and served as Chairman and CEO for 10 years prior to its acquisition by Abcam for $170 million. He was also a venture partner at OrbiMed Venture LLC , co-founded Immune-Onc and the Chinese Biopharmaceutical. His early leadership journey also includes senior level positions in Human Genome Sciences, Inc. and Mendel Biotechnology, Inc. where he established robust functional genomics and gene discovery programs for cutting-edge human drug discovery and plant-based applications. Dr. Yu shares his passion for science and discovery with fellow entrepreneurs by serving on the board of directors for fast-growing biotech companies, including Applied StemCell, Inc., and several professional organizations such as BayHelix, CABS, the National Foundation of Cancer Research, the Ray Wu Memorial Foundation, and the University of the Pacific in the US and China. He graduated from the Fudan University in China and received his PhD from University of California, Berkeley and a postdoctoral fellowship from the Harvard University. As a prominent biotechnologist and geneticist, Dr. Yu has co-authored 40 peer-reviewed scientific articles and has co-inventorship in more than 200 patents.